price
GM
NASDAQ · GMAB
Genmab A/S
Healthcare · Biotechnology
$34.15
Up+$1.50 (+4.59%)
Updated Sep 16, 2026, 9:29 AM
SID Score
7.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 19.89B
- P/E ratio
- 14.56
- Dividend yield
- 0.00%
- 52-week range
- $23.62 – $35.43
- Volume
- 3.09M
- Avg. volume
- 2.09M
Price performance
GMAB price history
1M range · 20 trading sessions · Daily adjusted prices
GMAB closed at $34.15 after 20 trading sessions, up 3.61% for the selected period.
- Last close
- $34.15
- Period change
- +3.61%
- Period low
- $32.23
- Period high
- $34.41
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $32.34 | $34.185 | $32.34 | $34.15 | 3.09M |
| Sep 14, 2026 | $32.79 | $32.96 | $32.52 | $32.65 | 1.41M |
| Sep 11, 2026 | $32.45 | $32.70 | $32.27 | $32.47 | 1.39M |
| Sep 10, 2026 | $32.46 | $32.68 | $32.21 | $32.23 | 1.02M |
| Sep 9, 2026 | $33.47 | $33.75 | $32.98 | $33.04 | 2.13M |
| Sep 8, 2026 | $33.71 | $33.84 | $33.36 | $33.53 | 1.55M |
| Sep 4, 2026 | $33.96 | $34.19 | $33.545 | $33.60 | 1M |
| Sep 3, 2026 | $34.63 | $34.66 | $34.08 | $34.41 | 890.95K |
| Sep 2, 2026 | $34.04 | $34.50 | $33.74 | $34.215 | 2.08M |
| Sep 1, 2026 | $33.33 | $33.67 | $33.15 | $33.29 | 1.56M |
| Aug 31, 2026 | $32.76 | $33.26 | $32.5401 | $33.16 | 1.73M |
| Aug 28, 2026 | $33.78 | $33.9295 | $33.115 | $33.23 | 1.52M |
| Aug 27, 2026 | $33.91 | $34.165 | $33.67 | $34.10 | 1.87M |
| Aug 26, 2026 | $33.78 | $33.90 | $33.36 | $33.75 | 3.09M |
| Aug 25, 2026 | $33.81 | $34.4699 | $33.72 | $34.36 | 2.03M |
| Aug 24, 2026 | $32.82 | $33.32 | $32.74 | $33.02 | 3.25M |
| Aug 21, 2026 | $33.36 | $33.98 | $33.28 | $33.45 | 2.54M |
| Aug 20, 2026 | $33.60 | $33.77 | $33.20 | $33.41 | 6.35M |
| Aug 19, 2026 | $33.41 | $34.185 | $33.255 | $34.11 | 3.23M |
| Aug 18, 2026 | $32.86 | $33.11 | $32.66 | $32.96 | 2.71M |
Latest GMAB news
The latest Smart Investors Daily articles mentioning GMAB.
Stock researchCompany · Overview
GMAB research
Overview
Company profile and research snapshot.
Company profile
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $41.25
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Jul 13, 2026 | JYSKE BANK | Buy | — |
| Jul 12, 2026 | TD COWEN | Hold | — |
| Jul 12, 2026 | H.C. WAINWRIGHT & CO., LLC | Buy | — |
| Jul 7, 2026 | DNB CARNEGIE | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.